In November 2020, the healthcare industry reported 58 deals worth $13.5 billion as compared to the last 12-month average (November 2019 to October 2020) of 81 deals worth $14.5 billion.
CBPO Group to acquire China Biologic Products Holdings, an integrated plasma-based biopharma company for an equity value of approximately $4.7 billion; Merck & Co to acquire all outstanding shares of VelosBio, a clinical-stage biopharmaceutical company developing novel, ROR1-directed therapeutics for $2.7 billion; Novo Nordisk A/S to acquire Emisphere Technologies (Emisphere), a drug delivery company with proprietary technologies, such as the Eligen SNAC technology, which enable oral formulations of therapeutics, for $1.8 billion are the three major deals that contributed 69 per cent of the total deal value during November 2020
| Deal Date | Acquirer (s) | Target | Deal Value ($ m) |
| 19-Nov-20 | CBPO Holdings Ltd (China) | China Biologic Products Holdings Inc (China) | 4,760.0 |
| 5-Nov-20 | Merck & Co Inc (US) | VelosBio Inc (US) | 2,750.0 |
| 6-Nov-20 | Novo Nordisk AS (Denmark) | Emisphere Technologies Inc (US) | 1,800.0 |
| 12-Nov-20 | Sumitovant Biopharma Inc (US) | Urovant Sciences Inc (US) | 681.0 |
| 2-Nov-20 | Royalty Pharma (US) | Residual Royalty Interest of cystic fibrosis (CF) treatments (US) | 650.0 |
Venture capital investments value increased in November 2020
The healthcare industry reported 91 venture capital (VC) deals worth $3.3 billion in November 2020, compared to the last 12-month average (November 2019 to October 2020) of 119 deals worth $2.7 billion.
RecBio, a biotechnology company raising $227 million in series B round of financing to build a production base and conduct clinical tests of its 9-valent HPV vaccine and recombinant COVID vaccine; D3 Bio, a biotechnology company focused on developing and commercialising precision medicines, raising $200 million in series A round of financing to support the development of its portfolio in oncology and immunology; and CARsgen Therapeutics Holdings, a biotechnology company raising $186 million in series C round of financing to accelerate global clinical trials of its cell therapy product candidate are the major VC deals reported in November 2020.
| Deal Date | Acquirer (s) | Target | Deal Value ($ m) |
| 11-Nov-20 | Legend Capital Co Ltd; LYFE Capital; Sequoia Capital; Vertex Ventures; HT Capital; Co-Stone Asset Management; Yuanbio Venture Capital; Qingsong Capital; China Everbright Limited | RecBio (China) | 227.0 |
| 17-Nov-20 | Boyu Capital Consultancy Co. Ltd; Undisclosed Investor(s); Sequoia Capital China; Temasek Holdings (HK) Limited; Matrix Partners China; WuXi AppTec Corporate Venture Fund | D3 Bio Inc (China) | 200.0 |
| 2-Nov-20 | Lilly Asia Ventures; Shiyu Capital Group LP; Summer Capital; Loyal Valley Capital; South China Venture Capital | CARsgen Therapeutics Holdings Limited (China) | 186.0 |
| 26-Nov-20 | CCB International Capital Ltd; Matrix Partners China; Efung Capital; Tianjin Venture Capital Management Co Ltd; Chengdu Tianfu International Bio-town Investment & Development Co LTD; Sinopharma-CICC Capital | Beijing Biostar Technologies Ltd (China) | 135.2 |
| 23-Nov-20 | Falcon Edge Capital, LP; Pura Vida Investments LLC; Christian Angermayer; Apeiron Investment Group Ltd; Galaxy Investment Partners Fund LLC; Future Ventures; Catalio Capital Management LP; Undisclosed Investor(s); Peter Thiel | Atai Life Sciences AG (Germany) | 125.0 |
Source: GlobalData